Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer

Jul. 06, 2022 11:15 AM ETBio-Techne Corporation (TECH)By: Ravikash, SA News Editor

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples


  • Bio-Techne (NASDAQ:TECH) said it launched the CE-IVD marked RNAscope ISH Probe High Risk HPV test in Europe for use in throat cancer.
  • The test is intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to help identify high-risk human papillomavirus (HPV), according to the company's July 6 press release.
  • Bio-Techne said HPV is a major cause of OPSCC and HPV has emerged as a diagnostic marker.
  • "We are excited to launch the new CE-IVD RNAscope ISH Probe High Risk HPV, which provides pathologists a highly accurate tool for the direct detection of HPV mRNA to inform treatment selection in oropharyngeal squamous cell carcinoma patients," said Kim Kelderman, president Diagnostics and Genomics, Bio-Techne.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.